

*Brief Report*

# Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-Like Reactions after the First Dose

Kazuhiro Araki <sup>1,\*</sup>, Nobuaki Shimizu <sup>2</sup>, Misa Iijima <sup>3</sup>, Hisashi Hosaka <sup>4</sup> and Yasuhiro Yanagita <sup>5</sup>

<sup>1</sup> Department of Medical Oncology, Gunma Prefectural Cancer Center, Ota City 373-8550, Gunma, Japan

<sup>2</sup> Department of Urology, Gunma Prefectural Cancer Center, Ota City 373-8550, Gunma, Japan

<sup>3</sup> Department of Pathology, Gunma Prefectural Cancer Center, Ota City 373-8550, Gunma, Japan

<sup>4</sup> Department of Gastrointestinal Medicine, Gunma Prefectural Cancer Center, Ota City 373-8550, Gunma, Japan

<sup>5</sup> Department of Breast Oncology, Gunma Prefectural Cancer Center, Ota City 373-8550, Gunma, Japan

\* Correspondence: kaz-araki@gunma-cc.jp; Tel.: +81-246-38-0771

**Supplemental table S1. Distribution of anti-spike protein immunoglobulin G titers (AU/mL) of BNT162b2 vaccine in the initial six participants.**

ID	GCC01	GCC02	GCC03	GCC04	GCC05	GCC06	GMT
After 1st dose	1	3.09	1.68	3.73	5.20	2.41	2.50
After 2nd dose	5.44	6.28	7.16	8.52	9.65	7.08	7.22
After 3M	4.23	3.61	4.50	5.86	6.85	4.48	4.81
After 6M	4.15	2.81	4.22	5.19	5.86	4.04	4.27
After 9M	3.85	2.41	3.79	4.13	5.22	3.54	3.73
After 3rd dose	8.04	8.72	9.86	10.25	11.29	9.36	9.53

ID: identification number; GCC01-06; each participant; GMT: geometric mean titer.